Candel Therapeutics, Inc. (CADL)Healthcare | Biotechnology | Needham, United States | NasdaqGM
13.07 USD
-0.68
(-4.945%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.07 0.00 (0.000%) ⇩ (Aug. 28, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:01 a.m. EDT
The immediate outlook is clouded by intense speculative fear. Despite a recent price bounce and a strong analyst consensus, the options market is screaming caution, with massive put buying at lower strikes indicating a belief that the stock will struggle to hold current levels. This disconnect suggests the recent rally may be fragile or driven by temporary news rather than a sustainable trend reversal. Long-term, the company sits in a precarious spot typical of biotech firms: it has no dividend to provide income, relies entirely on capital markets for funding, and carries significant debt relative to its cash reserves. While the business has shown resilience with a net positive return over the last four years despite severe interim losses, the lack of profitability and the heavy reliance on external financing create a high-risk profile. The balance sheet is not yet a fortress, and the path to breakeven remains uncertain. Until the company demonstrates consistent profitability or secures a major milestone-driven catalyst that stabilizes its funding needs, it remains a speculative hold rather than a core investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.110079 |
| AutoETS | 0.110415 |
| MSTL | 0.113743 |
| AutoARIMA | 0.115983 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 12.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.114 |
| Excess Kurtosis | -0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 39.259 |
| Market Cap | 1,000,097,664 |
| Forward P/E | -20.91 |
| Beta | -0.50 |
| Website | https://www.candeltx.com |
As of Aug. 22, 2026, 2:01 a.m. EDT: Speculators are aggressively positioning for a downside move in the near term, evidenced by heavy put volume and open interest at strikes significantly below the current price (e.g., $6, $9, $12), while call activity remains muted and concentrated at-the-money. Implied volatility is notably elevated for near-term puts compared to calls, suggesting fear of a sharp drop rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3464165 |
| Address1 | 117 Kendrick Street |
| Address2 | Suite 450 |
| All Time High | 14.78 |
| All Time Low | 0.66 |
| Ask | 13.51 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,473,050 |
| Average Daily Volume3 Month | 1,627,375 |
| Average Volume | 1,627,375 |
| Average Volume10Days | 1,473,050 |
| Beta | -0.502 |
| Bid | 7.49 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 1.657 |
| City | Needham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.07 |
| Current Ratio | 16.094 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 13.7999 |
| Day Low | 12.93 |
| Debt To Equity | 39.259 |
| Display Name | Candel Therapeutics |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -71,303,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.894 |
| Enterprise Value | 848,049,664 |
| Eps Current Year | -1.0025 |
| Eps Forward | -0.625 |
| Eps Trailing Twelve Months | -1.4 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.4768 |
| Fifty Day Average Change | 2.5931997 |
| Fifty Day Average Change Percent | 0.2475183 |
| Fifty Two Week Change Percent | 134.64165 |
| Fifty Two Week High | 14.0 |
| Fifty Two Week High Change | -0.9300003 |
| Fifty Two Week High Change Percent | -0.066428594 |
| Fifty Two Week Low | 4.35 |
| Fifty Two Week Low Change | 8.719999 |
| Fifty Two Week Low Change Percent | 2.0045977 |
| Fifty Two Week Range | 4.35 - 14.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,392,600,000 |
| Float Shares | 60,064,013 |
| Forward Eps | -0.625 |
| Forward P E | -20.911999 |
| Free Cashflow | -35,750,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 55 |
| Fullday Change | -0.68 |
| Fullday Change Percent | -4.94546 |
| Fullday Price | 13.0699 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14852999 |
| Held Percent Institutions | 0.66971 |
| Implied Shares Outstanding | 76,518,565 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. |
| Long Name | Candel Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,000,097,664 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_37378731 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -88,531,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,052,512,861 |
| Number Of Analyst Opinions | 8 |
| Open | 13.7 |
| Operating Cashflow | -56,023,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 916 5445 |
| Post Market Change | -0.0001001358 |
| Post Market Change Percent | -0.00076615 |
| Post Market Price | 13.0699 |
| Post Market Time | 1,787,961,250 |
| Previous Close | 13.75 |
| Price Eps Current Year | -13.037405 |
| Price Hint | 2 |
| Price To Book | 7.887749 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.89 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | -0.68 |
| Regular Market Change Percent | -4.94546 |
| Regular Market Day High | 13.7999 |
| Regular Market Day Low | 12.93 |
| Regular Market Day Range | 12.93 - 13.7999 |
| Regular Market Open | 13.7 |
| Regular Market Previous Close | 13.75 |
| Regular Market Price | 13.07 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,235,879 |
| Return On Assets | -0.28643999 |
| Return On Equity | -0.81844 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 76,518,565 |
| Shares Percent Shares Out | 0.16290002 |
| Shares Short | 12,463,333 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,961,675 |
| Short Name | Candel Therapeutics, Inc. |
| Short Percent Of Float | 0.2094 |
| Short Ratio | 10.24 |
| Source Interval | 15 |
| State | MA |
| Symbol | CADL |
| Target High Price | 29.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 21.0 |
| Target Median Price | 22.5 |
| Total Cash | 201,564,992 |
| Total Cash Per Share | 2.634 |
| Total Debt | 49,517,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.146125 |
| Two Hundred Day Average Change | 5.923875 |
| Two Hundred Day Average Change Percent | 0.8289632 |
| Type Disp | Equity |
| Volume | 1,235,879 |
| Website | https://www.candeltx.com |
| Zip | 2,494 |